阿替洛尔联合益心舒胶囊治疗稳定型心绞痛的临床观察

Clinical observation of Atenolol combined with Yixinshu capsule in treatment of stable angina pectoris

目的探讨阿替洛尔联合益心舒胶囊治疗稳定型心绞痛(SAP)患者的临床效果。方法采取随机抽签法将商丘市第一人民医院2018年1月—2021年3月收治的SAP患者80例,分为对照组(n=40)和观察组(n=40)。所有患者均接受常规治疗,在此基础上,对照组单用阿替洛尔,观察组采用阿替洛尔+益心舒胶囊,持续治疗3个月。对比两组临床效果;治疗前和治疗3个月的心功能[左室舒张末期内径(LVEDD)、心排血量(CO)、左室射血分数(LVEF)及舒张早期最大流速和心房收缩期最大流速比值(E/A)]和炎症指标[C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)以及白细胞介素-6(IL-6)];记录并比较两组不良反应发生情况。结果相较于对照组总有效率(80.00%),观察组(97.50%)更高,差异有统计学意义(P<0.05);治疗3个月,观察组LVEF、CO[(54.12±4.41)%、(5.31±0.53)L/min]水平高于对照组[(49.81±4.43)%、(4.72±0.52)L/min],LVEDD、E/A[(45.13±4.34)mm、(3.21±1.42)]水平低于对照组[(49.75±4.36)mm、(4.48±1.40)],差异有统计学意义(P<0.05);治疗3个月,观察组血清CRP、IL-6、TNF-α[(6.75±2.47)mg/L、(2.36±0.41)ng/L、(84.74±11.73)fmol/mL]低于对照组[(10.13±2.45)mg/L、(2.69±0.43)ng/L、(94.57±11.68)fmol/mL],差异有统计学意义(P<0.05);两组不良反应总发生率(10.00%、5.00%)对比,差异无统计学意义(P>0.05)。结论阿替洛尔联合益心舒胶囊治疗SAP的效果较好,可改善患者的心功能和炎症反应情况。

Objective To investigate the clinical effect of Atenolol and Yixinshu capsule in patients with stable angina pectoris(SAP)randomly.Methods Totally 80 patients with SAP treated in Shangqiu First People’s Hospital from January 2018 to March 2021 were randomly divided into control group(n=40)and observation group(n=40).All patients received routine treatment,on this basis,the control group was treated with atenolol alone,and the observation group was treated with atenolol combined with Yixinshu capsule,the treatment lasted for 3 months.the clinical effect of the two groups was compared;The cardiac function before and 3 months after treatment[left ventricular end diastolic diameter(LVEDD),cardiac output(CO),left ventricular ejection fraction(LVEF),ratio of early diastolic maximum velocity to atrial systolic maximum velocity(E/A)]and inflammatory indexes[C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)]were compared between the two groups;Adverse reactions were recorded and compared between the two groups.Results Compared the total effective rate of the control group(80.00%),the observation group(97.50%)was higher,with a statistical significant difference(P<0.05);After 3 months of treatment,levels of LVEF,CO[(54.12±4.41)%,(5.31±0.53)L/min]in the observation group were higher than those in the control group[(49.81±4.43)%,(4.72±0.52)L/min],levels of LVEDD,E/A[(45.13±4.34)mm,(3.21±1.42)]were lower than those in the control group[(49.75±4.36)mm,(4.48±1.40)],with statistical significant differences(P<0.05);After 3 months of treatment,the levels of CRP,IL-6 and TNF-αin the observation group[(6.75±2.47)mg/L,(2.36±0.41)ng/L,(84.74±11.73)fmol/mL]were lower than those in the control group[(10.13±2.45)mg/L,(2.69±0.43)ng/L,(94.57±11.68)fmol/mL],with statistical significant differences(P<0.05);There was no statistical significant difference in the total incidence of adverse reactions between the two groups(10.00%,5.00%).Conclusion Atenolol combined with Yixinshu capsule has better effect in the treatment of SAP,which can improve the cardiac function and inflammatory reaction of patients.